个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共6条记录   TAPENTADOL HYDROCHLORIDE: A NEXT-GENERATION, CENTRALLY ACTING ANALGESIC WITH TWO MECHANISMS OF ACTION IN A SINGLE MOLECULE [作者：Tzschentke, TM; Jahnel, U; Kogel, B; Christoph, T; Englberger, W; De Vry, J; Schiene, K; Okamoto, A; Upmalis, D; Weber, H; Lange, C; Stegmann, JU; Kleinert, R,期刊：Drugs of today, 页码：483-496 , 文章类型： Article，,卷期：2009年45-7] Tapentadol exerts its analgesic effects through mu opioid receptor agonism and noradrenaline reuptake inhibition in the central nervous system. Preclinical studies demonstrated that tapentadol is effective in a broad ran... BAZEDOXIFENE ACETATE: A NOVEL SELECTIVE ESTROGEN RECEPTOR MODULATOR FOR THE PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS [作者：Chines, AA; Komm, BS,期刊：Drugs of today, 页码：507-520 , 文章类型： Article，,卷期：2009年45-7] Postmenopausal osteoporosis is on increasing worldwide health concern affecting an estimated 200 million individuals. Despite a wide range of available treatment options, many patients ore not being treated or discontinu... MYCOPHENOLATE MOFETIL: AN UPDATE [作者：Villarroel, MC; Hidalgo, M; Jimeno, A,期刊：Drugs of today, 页码：521-532 , 文章类型： Review，,卷期：2009年45-7] Mycophenolic acid (MPA) is a potent, selective, noncompetitive and reversible inhibitor of inosine-5'-monophosphate deshydrogenase (IMPDH). By depleting guanosine and deoxyguanosine nucleotides in T and B lymphocytes it ... PLERIXAFOR HYDROCHLORIDE: A NOVEL AGENT FOR THE MOBILIZATION OF PERIPHERAL BLOOD STEM CELLS [作者：Cashen, AF,期刊：Drugs of today, 页码：497-505 , 文章类型： Article，,卷期：2009年45-7] Plerixafor is a novel small molecule that inhibits CXCR4 binding to SDF-1, on interaction that is a principal regulator of hematopoietic stem cell trafficking. Phase I studies demonstrated that a single plerixafor hydroc... A REVIEW OF CURRENT LITERATURE ON SECOND-GENERATION, SUCROSE-FORMULATED, FULL-LENGTH RECOMBINANT FACTOR VIII [作者：Konigs, C; von Hentig, N,期刊：Drugs of today, 页码：549-561 , 文章类型： Review，,卷期：2009年45-7] Recombinant factor VIII formulated with sucrose (rFVIII-FS) is a full-length recombinant human coagulation FVIII product which is formulated without the addition of human serum albumin. It is approved for the treatment a... THE USE OF MONOCLONAL ANTIBODIES AND RELATED AGENTS IN THE TREATMENT OF RESPIRATORY DISEASE [作者：Schachter, EN; Neuman, T,期刊：Drugs of today, 页码：533-548 , 文章类型： Review，,卷期：2009年45-7] Monoclonal antibodies were first developed in 1975. Since their introduction they hove hod a progressively increasing impact on different areas of medical diagnostics and therapeutics. Currently, many monoclonal antibodi...